Icon

AUGTYRO (NDA218213)- (40MG,160MG)

REPOTRECTINIB BRISTOL
40MG,160MG
No No
2036-Jul-24 2028-Nov-15
None None
None No
AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
0 0 0
Total Other Developers None
Drugs with Suitability No
40MG ** ** - - -
160MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.